DERMAPHARM HLDG INH O.N. news, videos and press releases
For more news please use our advanced search feature.
DERMAPHARM HLDG INH O.N. - More news...
DERMAPHARM HLDG INH O.N. - More news...
- EQS-News: Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies
- EQS-News: Sustained organic growth in high-margin existing branded pharmaceutical business
- EQS-News: Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share
- EQS-News: Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy
- EQS-News: Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges
- EQS-News: Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business
- EQS-News: Dermapharm Holding SE builds on success in Q3 2023
- EQS-News: Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall
- EQS-News: Dermapharm Holding SE: First half of 2023 is a success despite the challenging market environment
- EQS-News: Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 1.05 per share
- EQS-News: Dermapharm Holding SE invests in family-owned Austrian pharmaceutical company Montavit
- EQS-News: Dermapharm Holding SE: outstanding start to financial year 2023
- EQS-News: Dermapharm Holding SE: Dermapharm Holding SE surpasses one billion in revenue for first time in 2022 and maintains growth trajectory
- EQS-Adhoc: Dermapharm Holding SE: 2022 dividend
- EQS-News: Dermapharm Holding SE: Dermapharm Holding SE's revenue exceeds one billion for the first time
- EQS-News: Dermapharm Holding SE intensifies its internationalisation efforts by acquiring Arkopharma
- EQS-News: Dermapharm Holding SE successfully maintains growth trend as planned
- DGAP-News: Dermapharm Holding SE publishes H1 2022 financial report, confirms outlook for 2022 overall
- DGAP-News: Dermapharm Holding SE: Successful first half of 2022 in challenging market environment
- DGAP-News: Dermapharm commits to acquire the French market leader for herbal medicinal products and food supplements
- DGAP-Adhoc: Dermapharm Holding SE: binding offer to acquire Arkopharma Group
- DGAP-News: Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 2.17 per share
- DGAP-News: Dermapharm Holding SE: excellent start into financial year 2022
- DGAP-News: Dermapharm Holding SE records best ever year in 2021 - continuous growth in financial year 2022
- DGAP-News: Dermapharm Holding SE: Continuous growth of Group revenues and adjusted Group EBITDA in 2022
- DGAP-News: Dermapharm Holding SE: Most successful business year in the company's history - Adjusted Group EBITDA at the upper end of the outlook
- DGAP-News: Dermapharm successfully acquires C³ Group
- DGAP-News: Dermapharm Holding SE raises EBITDA forecast for the full year 2021
- DGAP-Adhoc: Dermapharm Holding SE raises EBITDA forecast for the full year 2021
- DGAP-News: Dermapharm Holding SE acquires C³-Group and expands its activities in the cannabis market
